Biotech Values

[Mufaso]

BioAge easily obtained funding to study preventing muscle loss with with Lilly’s Zepbound (tirzepatide) to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist. (This MOA looks to be a better approach than VERU's Enonosarm which is a SARM, IMO)

BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics

Funding to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, in combination with Lilly’s Zepbound (tirzepatide) and therapeutic pipeline

Azelaprag improves metabolic and muscle function and has potential as an oral drug to significantly increase weight loss and improve body composition in patients on GLP-1/incretin therapy

https://www.businesswire.com/news/home/20240213546755/en/